natgillin/translations-raw huggingface dataset:
A method for treating or delaying the progression or onset of Type 2 diabetes in a human comprising the step of administering to the human in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time što su namijenjeni upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa tip 2.
administering the dosage form to a mammal. 
(c) davanje doze sisavcu.
The method of claim 1 or 2, wherein said first CH3 domain-comprising polypeptide chain further comprises a lysine (K) residue at amino acid position 351 according to the EU numbering system. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni prvi polipeptidni lanac koji sadrži CH3 domenu dalje sadrži ostatak lizina (K) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije.
The wiring phase of the remote location relative to the wiring phase at the reference location is detected based on the first phase relation and the second phase relation. 
- < određivanje faze vodiča spomenute udaljene lokacije u odnosu na fazu vodiča na spomenutoj referentnoj lokaciji na osnovi spomenutog prvog faznog odnosa i spomenutog drugog faznog odnosa.
optionally isolating the compound of formula I or a pharmaceutically acceptable salt thereof as obtained in step a). 
€) po izboru, izolacije spoja formule I ili njegove farmaceutski prihvatljive soli koji su dobiveni u koraku d).
On the other hand, once the thermoblock 10 is in its proper steam-producing function, the valve 18 is in its closed state. 
5 druge strane, kada je termoblok 10 u svojoj pravoj funkciji proizvodnje vodene pare, ventil 18 je u svom zatvorenom stanju.
Headset apparatus according to any of claims 35 to 37 in which the headwear signal conduit means is exposed at a surface part of the earshell adjacent or within the surface portion of the earshell defining said headwear connection means, and said attachment means includes signal conduit means arranged to make electrical contact with said headwear signal conduit means when connected to the surface of the earshell thereby to permit electrical signals to be conveyed between the earshell and the attachment means. 
Slušalice prema bilo kojem od zahtjeva 35 do 37, naznačene time, da je naglavni signalni vod izložen na dijelu površine od školjke za uho, granično ili unutar površinskog odsječka od školjke za uho, koji definira navedeni naglavni spojni uređaj, a navedeni priključni uređaj obuhvaća signalni vod namješten tako, da uspostavlja električni kontakt s navedenim naglavnim signalnim vodom, kada je on spojen na površinu školjke za uho, čime se dopušta prijenos električnih signala između školjke za uho 1 priključnog uređaja.
A power control can be carried out by computational means to selectively deliver power to the two or three boilers. 
Kontrolu napajanja može se provesti pomoću računala radi selektivnog napajanja dva ili tri kotla.
An injection device suitable for intraepidermal and/or intradermally and/or subcutaneously comprising a sterile and injectable composition, said composition being prepared by a method comprising at least the steps of: 
Postupak za pripremu sterilnog i injektabilnog pripravka, naznačen time što postupak obuhvaća najmanje korake:
The process according to claim 1, wherein the natural calcium carbonate is marble, calcite, chalk, dolomite, limestone, or mixtures thereof. 
Postupak prema zahtjevu 1 ili zahtjevu 2, pri čemu je prirodni kalcij karbonat izabran od mramora, kalcita, krede, dolomita, vapnenca, ili njihovih smjesa.
wherein the model is a mixture model, optionally wherein the mixture model accounts for sequencing error; wherein the DNA obtained from a bodily fluid of a pregnant individual is cell-free DNA obtained from the plasma of the pregnant individual; 
Postupak prema patentnom zahtjevu 1, naznačen time što DNK dobivena iz tjelesne tekućine trudne osobe predstavlja DNK oslobođenu od stanica koja je dobivena iz plazme trudne osobe.
The slidable part can be slidable between a protected position wherein it is stored in the packaging and an accessible position wherein it has been slided out of the packaging and thus is accessible. 
Dio koji može klizati može klizati između jednog zaštićenog položaja u kojemu je pohranjen u pakiranju i jednog pristupačnog položaja u kojemu je iskliznuo iz pakiranja i na taj način je bio pristupačan.
The pharmaceutical composition according to claim 9, which is a dosage form suitable for oral administration. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je u dozirnom obliku pogodnom za oralnu primjenu.
23, 24 and 25, wherein said antibody preferably increases ITIM phosphorylation of FcYRIIB of Daudi cells about 4 to 10-fold in comparison to Daudi cells not treated with said antibody. 
32, 33 i 34, gdje navedeno protutijelo povećava fosforiliranje ITIM u FcyRIIB kod Daudi stanica otprilike 4 do 10 puta u usporedbi s Daudi stanicama neobrađenim navedenim protutijelom.
and neutralizing dorzolamide camphorsulfonate of formula (III) to obtain dorzolamide of formula (I) 
WI i c) neutraliziracijom dorzolamid kamforsulfonata formule (III) kako bi se dobio dorzolamid formule (1)
glycols) and their derivatives, and oils (e.g. 
glikole) i njihove derivate, te ulja (npr.
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 
ili njegova farmaceutski prihvatljiva sol, stereoizomer, i/ili N-oksid.
where n=5 to 9, which is reduced in the hydrogen atmosphere at the presence of a catalyst to alcohol of the general formula VI, 
gdjesen=5do9 koji se u atmosferi vodika u prisutnosti katalizatora svodi na alkohol opće formule VI, u e
This upgrade should fulfill the following three requirements: 
Takvo poboljšanje treba ispuniti tri sljedeća zahtjeva: 1)
Extent of Hydrolysis (%) 
Stupanj hidrolize (%)
a third domain VLB being a light chain variable domain specific for the second antigen B; and 
- < druga domena VEB i treća domena VLB su specifične za tumorsku stanicu;
Figure 7 is a view of the device of Figure 3 after assembly; 
- - slika 7 je pogled na uređaj iz slike 3 nakon sastavljanja;
wherein, in step c), a first resist layer, which can be activated by means of electromagnetic radiation, is applied to the side of the metal layer facing away from the first decorative ply, and wherein the first resist layer is illuminated by means of said electromagnetic radiation using an illumination mask, and 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time, da se u stupnju c) prvi otporni sloj (6), koji se može aktivirati pomoću elektromagnetskog zračenja, nanosi na onu stranu metalnog sloja (5) koja gleda suprotno od prvog dekorativnog sloja (3), i da se prvi otporni sloj (6), uz primjenu ekspozicijske maske, eksponira navedenim elektromagnetskim zračenjem.
Wind system (1) according to claim 1, characterised in that said kites (2) are equipped with an actuating and stabilising system of a sideslip manoeuvre. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da spomenuta opruga bude pritisnuta zbog djelovanja napetosti spomenutog užeta (4).
A compound according to claim 3 or 4, wherein each of R1 and R'1, or said fused ring structure formed thereby, is optionally substituted by at least one substituent selected from the group consisting of: fluorine and chlorine atoms, hydroxy groups, linear or branched alkoxy groups containing from 1 to 5 carbon atoms, linear or branched alkyl groups containing from 1 to 5 carbon atoms, trifluoromethyl and trifluoromethoxy groups, and -CN groups, and wherein, when there is more than one substituent, then each said substituent is the same or different. 
Spoj prema zahtjevu 3 ili 4, naznačen time da svaki R, 1 R',, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno je supstituirana sa barem jednim supstituentom odabranim iz skupine koja sadrži: atome fluora ili klora, hidroksi skupine, ravne ili razgranate alkoksi skupine koje sadrže od 1 do 5 atoma ugljika, ravne ili razgranate alkilne skupine koje sadrže od 1 do 5 atoma ugljika, trifluorometil i trifluorometoksi skupine, i -CN skupine, te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit,
A host cell as defined in any one of claims 1 to 3, wherein the second vector comprises a nucleic acid molecule of SEQ ID NO: 54. 
Molekula nukleinske kiseline u skladu s patentnim zahtjevom 3, naznačena time što sadrži SEQ ID NO:54 i SEQ ID NO:59.
A non-aqueous patch comprising 0.5 to 7 mass% lidocaine, and a dissolving agent composed of isostearic acid and dipropylene glycol which are contained in a base of plaster, the plaster being held by a support, of which strength of 50% stretched to longitudinal direction is less than 2,000g/50mm and of biaxially-oriented stretch cloth, wherein the adhesive power of the patch, of 180 degree taking off method defined in Z0237 of JIS (Japanese Industrial Standards), is from 0.4N/width 25mm to 5N/width 25mm, and wherein the proportion of dissolving agent and lidocaine is 0.5 to 5 mass% of dissolving agent relative to 1 mass% of lidocaine. 
Nevodeni flaster koji sadrži od 0,5 do 7 masenih postotaka lidokaina i sredstvo za otapanje sastavljeno od izostearinske kiseline i dipropilen glikola koji su sadržani u bazi flastera, a flaster se drži pomoću nosača, čija čvrstoća od 50% rastegnuta u uzdužnom smjeru je manja od 2.000g/50mm te od biaksijalno orijentirane rastezljive tkanine, naznačen time da je adhezivna snaga flastera, metodom skidanja od 180 stupnjeva koja je definirana u Z0237 JIS-a (Japanski Industrijski Standardi), od 0.4N/širina 25mm do 5N/širina 25 mm, te time što je udio sredstva za otapanje i lidokaina od 0,5 do 5 masenih postotaka otapala u odnosu na 1 maseni postotak lidokaina.
IEX relies on charge interactions between the protein of interest and the ion exchange matrix, which is generally composed of resins, such as agarose, dextran, and cross-linked cellulose and agarose, that are covalently bound to a charged group (Amersham Biosciences B 1998). 
IEX se temelji na interakcijama nabaoje između željenog proteina i matriksa za ionsku izmjenu, koji se generalno sastoji od smola, poput agaroze, dekstrana i unakrsno-povezane celuloze i agaroze, koji su kovalentno povezani sa nabijenom skupinom (Amersham Biosciences B 1998).
Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), or nitrogen (optionally substituted with oxygen), provided that no more than two of Q, D, X, and T are nitrogen; 
Q, D, X i T neovisno predstavljaju ugljik (supstituiran s vodikom ili izbornim supstituentima kako je naznačeno ovdje), ili dušik (izborno supstituiran s kisikom), pod uvjetom da najviše 2 od Q, D, X i T su dušici;
A pharmaceutical combination comprising a therapeutically effective amount of a composition comprising: 
Farmaceutska kombinacija, naznačena time što sadrži terapijski djelotvornu količinu pripravka koji sadrži:
The oil according to any of the claims 1 to 18 comprising: a lipid fraction comprising fatty acids in concentrations of from 90% to 100% by weight, preferably from 95% to 100% by weight; vitamin F in concentrations of from 45% to 60% by weight, preferably from 46% to 54% by weight; omega 3 in concentrations of from 0.5% to 2% by weight, preferably from 0.8% to 1.8% by weight; and also comprising Y-oryzanol in concentrations of from 0.01% to 0.10% over the total weight of the lipid fraction, preferably from 0.02% to 0.04%; vitamin E in concentrations of from 0.01% to 0.40% over the weight of the lipid fraction, preferably from 0.018% to 0.025%. 
Ulje prema jednom od zahtjeva 1 do 18, naznačeno time, da obuhvaća: lipidnu frakciju koja sadrži masne kiseline u koncentracijama od 90 do 100 masenih %, poželjno od 95 do 100 masenih %; vitamin F u koncentracijama od 45 do 60 masenih %, poželjno od 46 do 54 masenih %; omega 3 u koncentracijama od 0,5 do 2 masenih %, poželjno od 0,8 do 1,8 masenih %; i također obuhvaća y-orizanol u koncentracijama od 0,01 do 0,10 % preko ukupne mase lipidne frakcije, poželjno od 0,02 do 0,04 %; vitamin E u koncentracijama od 0,01 do 0,04 % preko mase lipidne frakcije, poželjno od 0,018 do 0,025 %.
Figure 3 is an XRPD spectrum of pellets produced in Example 1 measured after 1 month storage in an open plastic container at 25°C and 60% RH; 
Slika3 je XRPD spektar peleta dobivenih u Primjeru 1 izmjeren nakon mjesec dana skladištenja u otvorenom plastičnom spremniku na 25 *C, uz 60 % relativne vlage;
subjecting said profile (15) to a polymerization process, characterized by said outer surface (15B) of said profile (15) having a sinusoidal shape with respect to an axial cross-sectional plane. 
podvrgavanje spomenutog profila (15) procesu polimerizacije, naznačeno time da spomenuta vanjska površina (15B) spomenutog profila (15) ima sinusoidan oblik u odnosu na jednu ravninu osnog poprečnog presjeka.
The nanoparticles according to anyone of claims 1 to 11, wherein the cancer is a solid tumor or a hematopoietic tumor, preferably selected from the group consisting of hepatocellular carcinoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, diffuse large B-cell lymphoma, small cell lung cancer, colorectal cancer, pancreas cancer, breast cancer, ovary cancer, uterine cancer, cervix cancer, head and neck cancer, brain cancer, bladder cancer, multiple myeloma, neuroblastoma, Ewing's sarcoma, osteosarcoma, soft tissue sarcoma, thyroid cancer, prostate cancer, stomach cancer, nephroblastoma, Kaposi's sarcoma, and non-Hodgkins lymphoma. 
Nanočestice za uporabu prema bilo kojem od zahtjeva 1-8, naznačene time da karcinom je solidni tumor ili hematopoetski tumor, poželjno odabran iz skupine koja sadrži hepatocelularni karcinom, akutnu limfoblastičnu leukemiju, akutnu mijeloičnu leukemiju, kroničnu mijelogenu leukemiju, Hodgkinsovu bolest, difuzni B- velikostanični limfom, rak pluća malih stanica, rak debelog crijeva, rak gušterače, rak dojke, rak jajnika, rak maternice, rak grlića maternice, rak glave i vrata, rak mozga, rak mjehura, multipli mijelom, neuroblastom, Ewingov sarkom, osteosarkom, sarkom mekog tkiva, rak štitnjače, rak prostate, rak želuca, nefroblastom, Kapozijev sarkom, te ne-Hodgkinov limfom.
The reaction was stirred at room temperature for 2.5 hours. 
Reakcijska smjesa je bila miješana na sobnoj temperaturi kroz 2.5 sata.
The system of claim 16 wherein the controller component and the same electrical source are disposed in a wearable housing. 
Sustav sukladno zahtjevu 13 pri čemu su kontrolna komponenta i isti električni izvor smješteni u nosivom kućištu.
An antibody directed against the extracellular part of Sortilin and capable of inhibiting binding of a pro-neurotrophin to a binding site on the Sortilin receptor, wherein the antibody is directed against a sequence having SEQ ID NO: 25, SEQ ID NO. 26, SEQ ID NO. 27 or SEQ ID NO. 28 for use in treatment of human neurodegenerative disorders. 
Antitijelo usmjereno protiv vanćelijskog dijela sortilina i sposobno inhibirati vezanje proneurotrofina na mjesto vezivanja na receptor sortilina, gdje je antitijelo usmjereno protiv sekvence koja se sastoji od RGGRIFRSSDFAKNF za uporabu u liječenju ljudskih neurodegenerativnih poremećaja.
In alternative aspects, the present description provides a method of treating a rheumatic disease in a patient undergoing methotrexate treatment comprising a step of administering an agent capable of activating CD4+CD25+ regulatory T cells, and a method of treating a rheumatic disease in a patient undergoing treatment with an agent capable of activating CD4+CD25+ regulatory T cells comprising a step of administering methotrexate. 
Pripravak koji sadrži metotreksat 1 namijenjen je upotrebi u liječenju reumatske bolesti kod pacijenta, gdje se pacijent liječi sredstvom koje može aktivirati regulacijske T-stanice CD4+CD25+, naznačen time što je sredstvo humanizirano protutijelo protiv CD4 koje sadrži V domenu lanca H i V domenu lanca L, te što:
The nucleic acid sequence of claim 13, wherein the fusion protein further comprises an Fc fragment of an immunoglobulin. 
Sekvenca nukleinske kiseline, koja kodira fuzijski protein sukladno bilo kojem od patentnih zahtjeva 1-5.
Wind system (1) according to claim 1, characterised in that said recovering system (8) is equipped with at least one articulated joint (9) in order to be partly or completely able to be oriented. 
Vjetreni sustav (1) prema zahtjevu 9, naznačen time da se prilikom manevra bočnog klizanja spomenuti bočni izbojci podignu pod djelovanjem protoka.
The process of claim 1, wherein said PSA adsorbs at a temperature of at least 65° C. and a pressure of at least 500 psia. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni PSA adsorbira na temperaturi od najmanje 150 *C i pod tlakom od najmanje 5516 kPa (800 ps1a).
An electrically heated smoking system for receiving an aerosol-forming substrate, the system comprising: 
Električno grijani sustav za pušenje namijenjen prihvatu supstrata koji stvara aerosol (407), gdje sustav sadrži:
The antigen may be any protein or fragment thereof against which it is desirable to raise an immune response, in particular a CTL response, but also a Th17 response or a Treg response. 
Uporaba prema zahtjevu 11, naznačena time, da imunološka reakcija je Treg reakcija i pri čemu je antigen, onaj protiv kojega je poželjno sprečavati ili smanjivati neželjenu imunološku reakciju.
The optimized viral polypeptide of clause 40, wherein said optimized viral polypeptide comprises any one of the amino acid sequences set forth in SEQ ID NOS:1-29. 
Cjepivo prema zahtjevu 5, gdje spomenuto cjepivo sadrži jedan ili više vektora koji kodiraju: barem dva različita optimizirana gag polipeptida koji sadrže sekvence amino kiselina prikazane u SEQ ID NOs:
a conductive composite layer overcoating the metallic antenna underbody; wherein the conductive composite layer comprises a plurality of carbon nanotubes and a polymer; wherein each of the plurality of carbon nanotubes is in contact with at least one other of the plurality of carbon nanotubes; and wherein the conductive composite layer acts as an amplifier for the metallic antenna underbody. 
Hibridna antena koja sadrži: metalnu osnovnu konstrukciju antene; i provodni kompozitni sloj koji prekriva metalnu noseću konstrukciju antene; pri čemu provodni kompozitni sloj sadrži mnoštvo ugljičnih nanocijevi i polimer; pri čemu je svaka iz mnoštva ugljičnih nanocijevi u kontaktu najmanje sa jednom drugom iz mnoštva ugljičnih nanocijevi; i pri čemu provodni kompozitni sloj djeluje kao pojačivač za metalnu osnovnu konstrukciju antene.
is substituted or non-substituted C6-C10 aryl or C1-C9 heteroaryl wherein the heteroatoms independently are selected from N, O and S; or substituted or non-substituted mono- or bicyclic C3-12 cycloalkyl or C1-C9 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; as well as pharmaceutically acceptable salts thereof. 
R* je supstituirani ili nesupstituirani C4.,, aril ili C,.9 heteroaril pri čemu su heteroatomi nezavisno odabrani između N, O 1 S; ili supstituirani ili nesupstituirani mono- ili biciklički C3.,2 cikloalkil ili Cy9g heterociklil pri čemu su heteroatomi nezavisno odabrani između N, O16S; i njihove farmaceutski prihvatljive soli.
A compound according to any one of claims 1 to 13 for use in the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, neurodegeneration, amyotrophic lateral sclerosis, stroke, transient ischemic attack or uveitis. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time, da se upotrebljava u liječenju ili profilaksi boli, ateroskleroze, starosne makularne degeneracije, dijabetičke retinopatije, glaukoma, okluzije retinalne vene, retinopatije kod nedonoščadi, ishemijskog okularnog sindroma, geografske atrofije, dijabetesa mellitusa, upale, upalne bolesti crijeva, ishemijsko-reperfuzijske ozljede, akutnog zatajenja jetre, jetrene fibroze, plućne fibroze, fibroze bubrega, sistemske fibroze, akutnog odbacivanja alogenskih presadaka, kronične alogenske nefropatije, dijabetičke nefropatije, glomerulonefropatije, kardiomiopatije, zatajenja srca, ishemije miokarda, infarkta miokarda, sistemske skleroze, toplinske ozljede, opekline, hipertrofičnih ožiljaka, keloidnih ožiljaka, pireksije povezane s gingivitisom, ciroze ili tumora jetre, za regulaciju koštane mase, neurodegeneracije, amiotrofične lateralne skleroze, moždanog udara, prolaznog ishemijskog udara ili uveitisa.
The facility according to claim 1, wherein at least one compressor is arranged along at least one of said transport pipes of the utilization unit. 
Postrojenje u skladu s patentnim zahtjevom 17, naznačeno time što se najmanje jedan kompresor (A41, A42, A43) nalazi uz najmanje jednu od navedenih transportnih cijevi jedinice za upotrebu (AB).
The solid pharmaceutical composition of embodiment 1, wherein said solid pharmaceutical composition disintegrates within 30 seconds. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 2, naznačeno time da se navedena tableta rastapa unutar 30 sekundi.
Preferably, the total amount of co-solvent used in combination with water present in the composition in accordance with the present invention is sufficient volatile to provide acceptable drying times of the nail topical formulation. 
Poželjno, ukupna količina kootapala koja se koristi u kombinaciji s vodom prisutnom u pripravku u skladu s ovim izumom dovoljno je hlapljiva da omogući prihvatljivo vrijeme sušenja topikalne formulacije za nokte.
The composition for use of claim 1 or 2, wherein the composition is formulated for oral administration. 
Smjesa za uporabu prema zahtjevu 1 ili 2, gdje je bolest CMT, poželjno CMTIA.
− represents an anion associated with the positive charge of the N atom. 
R1 predstavlja anion povezan s pozitivnim nabojem na N atomu; i
Phycoerythrin-conjugated anti-CD11b antibody and phycoerythrin-conjugated isotype control antibody were obtained from BD Biosciences, Inc., San Jose, Calif., U.S.A. MethoCult™ M3234 methylcellulose medium (2.5% methylcellulose in IMDM, supplemented with fetal bovine serum, bovine serum albumin, rh insulin, h transferrin, 2-mercaptoethanol, and L-glutamine) was obtained from StemCell Technologies, Inc., Vancouver, Canada, and was diluted (to 1% methylcellulose concentration) in accordance with the manufacturer's directions. 
Phycoerythrin-konjugirani anti-CD11b antitijelo i phycoerythrin- konjugirani izotip kontrol antitijelo dobiveni su iz BD Biosciences, Inc., San Jose, California, USA. MethocultTM M3234 metilcelulozni medij (2.5% metilceluloze u IMDM, dopunjen fetal bovine serumom, bovine serum albumin, rh inzulin, h transferin, 2-merkaptoetanol, i L-glutamin) dobiveni su od StemCell Technologies, Inc., Vancouver, Canada, i razrijeđen (do 1% concentracije metilceluloze) u skladu s uputama za rad.